Zulvac 1 Ovis


inactivated bluetongue virus, serotype-1

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 11/04/2017

Authorisation details

Product details
Zulvac 1 Ovis
Agency product number
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Anatomical therapeutic chemical veterinary (ATCvet) codes
Accelerated assessmentAccelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

23/03/2017 Zulvac 1 Ovis - EMEA/V/C/002335 - IG/0747


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group


Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Assessment history

How useful was this page?

Add your rating